ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
-0.76%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$185M
AUM Growth
+$185M
(+209%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
68.82%
Top 10 Holdings %
Top 10 Hldgs %
67.37%
Holding
37
New
12
Increased
18
Reduced
–
Closed
7
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$15.1M |
| 2 |
Insmed
INSM
|
$14.7M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$12M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$9.27M |
| 5 |
Inogen
INGN
|
$9.24M |
Top Sells
| 1 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$3.41M |
| 2 |
Illumina
ILMN
|
$2.58M |
| 3 |
Heron Therapeutics
HRTX
|
$1.66M |
| 4 |
Penumbra
PEN
|
$1.65M |
| 5 |
CVS Health
CVS
|
$1.02M |
Sector Composition
| 1 | Healthcare | 89.71% |
| 2 | Industrials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $18.7M | 10.13% | 730,440 +575,553 | +372% | +$14.7M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $16.5M | 8.95% | 314,217 +228,556 | +267% | +$12M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15.1M | 8.18% | +176,325 | New | +$15.1M |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $14.3M | 7.72% | 525,730 +341,828 | +186% | +$9.27M |
|
|
5
Inogen
INGN
$216M
| $12.8M | 6.94% | 191,970 +138,395 | +258% | +$9.24M |
|
6
PTC Therapeutics
PTCT
$3.92B
| $12.6M | 6.84% | 280,542 +127,714 | +84% | +$5.75M |
|
7
Gilead Sciences
GILD
$140B
| $10M | 5.43% | 148,281 +78,402 | +112% | +$5.3M |
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $9.12M | 4.94% | +63,940 | New | +$9.12M |
|
9
Centene
CNC
$14.3B
| $7.74M | 4.19% | 147,638 +88,545 | +150% | +$4.64M |
|
10
UnitedHealth
UNH
$281B
| $7.51M | 4.07% | 30,767 +19,903 | +183% | +$4.86M |
|
|
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $6.35M | 3.44% | 126,655 +64,094 | +102% | +$3.21M |
|
12
Natera
NTRA
$23.1B
| $6.01M | 3.25% | 217,899 +187,441 | +615% | +$5.17M |
|
|
CBIO
13
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $5.94M | 3.21% | 498,023 +361,033 | +264% | +$4.3M |
|
14
Twist Bioscience
TWST
$1.63B
| $4.99M | 2.7% | 171,903 +148,170 | +624% | +$4.3M |
|
15
Elevance Health
ELV
$71.8B
| $4.68M | 2.53% | +16,581 | New | +$4.68M |
|
16
CRISPR Therapeutics
CRSP
$4.71B
| $4.59M | 2.49% | +97,499 | New | +$4.59M |
|
17
Opko Health
OPK
$1.1B
| $3.97M | 2.15% | +1,628,666 | New | +$3.97M |
|
|
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
| $3.91M | 2.12% | 443,973 +360,362 | +431% | +$3.17M |
|
19
Pacira BioSciences
PCRX
$1.2B
| $3.69M | 2% | 84,735 +70,854 | +510% | +$3.08M |
|
|
XLRN
20
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.39M | 1.83% | 82,473 +52,348 | +174% | +$2.15M |
|
21
Avantor
AVTR
$9.18B
| $2.35M | 1.27% | +122,962 | New | +$2.35M |
|
|
NCNA
22
NuCana
NCNA
$6.09M
| $1.69M | 0.91% | 162,414 +117,021 | +258% | +$1.21M |
|
23
Sarepta Therapeutics
SRPT
$1.78B
| $1.68M | 0.91% | +11,050 | New | +$1.68M |
|
24
Verrica Pharmaceuticals
VRCA
$52.8M
| $1.54M | 0.84% | 132,820 +62,362 | +89% | +$724K |
|
25
iRhythm Technologies
IRTC
$5.46B
| $1.18M | 0.64% | 14,854 +3,876 | +35% | +$307K |
|